Blaise Lippa
Overview
Explore the profile of Blaise Lippa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lemay S, Montesinos M, Grobs Y, Yokokawa T, Shimauchi T, Mougin M, et al.
Circulation
. 2025 Jan;
PMID: 39829438
Background: Pulmonary arterial hypertension (PAH) is characterized by obliterative vascular remodeling of the small pulmonary arteries (PAs) and progressive increase in pulmonary vascular resistance leading to right ventricular failure. Although...
2.
Harrison B, Dowling J, Bursavich M, Troast D, Chong K, Hahn K, et al.
J Med Chem
. 2024 Oct;
67(21):18656-18681.
PMID: 39446989
Inhibition of integrin αvβ6 is a promising approach to the treatment of fibrotic disease such as idiopathic pulmonary fibrosis. Screening a small library combining head groups that stabilize the bent-closed...
3.
Lemay S, Montesinos M, Grobs Y, Yokokawa T, Shimauchi T, Romanet C, et al.
bioRxiv
. 2024 Jun;
PMID: 38854025
One Sentence Summary: The α5β1 integrin plays a crucial role in pulmonary vascular remodeling.
4.
Zhang X, Cross J, Romero J, Heifetz A, Humphries E, Hall K, et al.
J Comput Aided Mol Des
. 2018 Mar;
32(4):573-582.
PMID: 29582229
Antagonism of CCR9 is a promising mechanism for treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. There is limited experimental data on CCR9 and its ligands, complicating...
5.
Zhang J, Chan A, Lippa B, Cross J, Liu C, Yin N, et al.
Bioorg Med Chem Lett
. 2017 Mar;
27(8):1670-1680.
PMID: 28302397
The emergence and spread of multidrug-resistant (MDR) Gram negative bacteria presents a serious threat for public health. Novel antimicrobials that could overcome the resistance problems are urgently needed. UDP-3-O-(R-3-hydroxymyristol)-N-acetylglucosamine deacetylase...
6.
Pandya B, Baber C, Chan A, Chamberlain B, Chandonnet H, Goss J, et al.
Bioorg Med Chem Lett
. 2016 Jun;
26(14):3322-3325.
PMID: 27256913
Irritable bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) are serious chronic diseases affecting millions of patients worldwide. Studies of human chemokine biology has suggested C-C...
7.
Discovery of Pyrazolopyridones as a Novel Class of Gyrase B Inhibitors Using Structure Guided Design
Cross J, Zhang J, Yang Q, Mesleh M, Romero J, Wang B, et al.
ACS Med Chem Lett
. 2016 Apr;
7(4):374-8.
PMID: 27096044
The ATPase subunit of DNA gyrase B is an attractive antibacterial target due to high conservation across bacteria and the essential role it plays in DNA replication. A novel class...
8.
Mesleh M, Cross J, Zhang J, Kahmann J, Andersen O, Barker J, et al.
Bioorg Med Chem Lett
. 2016 Jan;
26(4):1314-8.
PMID: 26786695
Inhibitors of the ATPase function of bacterial DNA gyrase, located in the GyrB subunit and its related ParE subunit in topoisomerase IV, have demonstrated antibacterial activity. In this study we...
9.
Zhang J, Yang Q, Romero J, Cross J, Wang B, Poutsiaka K, et al.
ACS Med Chem Lett
. 2015 Oct;
6(10):1080-5.
PMID: 26487916
Antibacterials with a novel mechanism of action offer a great opportunity to combat widespread antimicrobial resistance. Bacterial DNA Gyrase is a clinically validated target. Through physiochemical property optimization of a...
10.
Zhang J, Yang Q, Cross J, Romero J, Poutsiaka K, Epie F, et al.
J Med Chem
. 2015 Oct;
58(21):8503-12.
PMID: 26460684
The emergence and spread of multidrug resistant bacteria are widely believed to endanger human health. New drug targets and lead compounds exempt from cross-resistance with existing drugs are urgently needed....